Skip to content

Effect of zinc supplementation in major depression

Effect of zinc supplementation on depression and certain inflammatory cytokines depression in patients with major

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201110187836N1
Enrollment
44
Registered
2011-11-06
Start date
2011-10-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depression. Severe depressive episode without psychotic symptoms

Interventions

Intervention 1: Taking a Zinc sulfate capsule, 25 mg once a day for 12 weeks (intervention). Intervention 2: Taking a placebo capsule once a day for 12 weeks.
Treatment - Drugs
Placebo
Taking a Zinc sulfate capsule, 25 mg once a day for 12 weeks (intervention)
Taking a placebo capsule once a day for 12 weeks

Sponsors

Department of Clinical Nutrition and Diet therapy, Faculty of Nutrition Sciences and Food Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: - A diagnosis of major depressive disorder - Have no current medical illness (diabetes, cancer, cardiovascular, inflammatory, liver or renal diseases) - No antepartum or postpartum depression - Current treatment with medication except for depressive disorder - Current use of multivitamin-mineral supplement Exclusion criteria: - pregnancy or lactation - any change in medication - A diagnosis of a new medical illness during study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Depression. Timepoint: at the begining, after 6 and 12 weeks of supplementation. Method of measurement: Hamilton and Beck Depression Rating Scale.

Secondary

MeasureTime frame
Plasma concentration of brain-derived growth factor. Timepoint: Before and after 12 weeks of treatment. Method of measurement: Biochemical assay.;Plasma concentration of Tumor Necrosis Factor-a. Timepoint: Before and after 12 weeks of treatment. Method of measurement: Biochemical assay.;Plasma concentration of Interleukin-6. Timepoint: Before and after 12 weeks of treatment. Method of measurement: Biochemical assay.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Ranjbar

Shahid Beheshti University of Medical Sciences

alnaz_3000@yahoo.com+98 21 2237 6467

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026